Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31


Pulmonary Iron Homeostasis in Hepcidin Knockout Mice.

Deschemin JC, Mathieu JRR, Zumerle S, Peyssonnaux C, Vaulont S.

Front Physiol. 2017 Oct 17;8:804. doi: 10.3389/fphys.2017.00804. eCollection 2017.


AMPK is not required for the effect of metformin on the inhibition of BMP6-induced hepcidin gene expression in hepatocytes.

Deschemin JC, Foretz M, Viollet B, Vaulont S.

Sci Rep. 2017 Oct 4;7(1):12679. doi: 10.1038/s41598-017-12976-2.


Hepcidin knockout mice spontaneously develop chronic pancreatitis owing to cytoplasmic iron overload in acinar cells.

Lunova M, Schwarz P, Nuraldeen R, Levada K, Kuscuoglu D, Stützle M, Vujić Spasić M, Haybaeck J, Ruchala P, Jirsa M, Deschemin JC, Vaulont S, Trautwein C, Strnad P.

J Pathol. 2017 Jan;241(1):104-114. doi: 10.1002/path.4822. Epub 2016 Dec 1.


Iron Homeostasis and Inflammatory Status in Mice Deficient for the Cystic Fibrosis Transmembrane Regulator.

Deschemin JC, Allouche S, Brouillard F, Vaulont S.

PLoS One. 2015 Dec 28;10(12):e0145685. doi: 10.1371/journal.pone.0145685. eCollection 2015.


The microbiota shifts the iron sensing of intestinal cells.

Deschemin JC, Noordine ML, Remot A, Willemetz A, Afif C, Canonne-Hergaux F, Langella P, Karim Z, Vaulont S, Thomas M, Nicolas G.

FASEB J. 2016 Jan;30(1):252-61. doi: 10.1096/fj.15-276840. Epub 2015 Sep 14.


Expression and purification of a new recombinant camel hepcidin able to promote the degradation of the iron exporter ferroportin1.

Boumaiza M, Jaouen M, Deschemin JC, Ezzine A, Ben Khalaf N, Vaulont S, Marzouki MN, Sari MA.

Protein Expr Purif. 2015 Nov;115:11-8. doi: 10.1016/j.pep.2015.04.016. Epub 2015 Jul 11.


Matriptase-2 is essential for hepcidin repression during fetal life and postnatal development in mice to maintain iron homeostasis.

Willemetz A, Lenoir A, Deschemin JC, Lopez-Otin C, Ramsay AJ, Vaulont S, Nicolas G.

Blood. 2014 Jul 17;124(3):441-4. doi: 10.1182/blood-2014-01-551150. Epub 2014 Jun 5.


Hepcidin knockout mice fed with iron-rich diet develop chronic liver injury and liver fibrosis due to lysosomal iron overload.

Lunova M, Goehring C, Kuscuoglu D, Mueller K, Chen Y, Walther P, Deschemin JC, Vaulont S, Haybaeck J, Lackner C, Trautwein C, Strnad P.

J Hepatol. 2014 Sep;61(3):633-41. doi: 10.1016/j.jhep.2014.04.034. Epub 2014 May 6.


Role of hepcidin in the setting of hypoferremia during acute inflammation.

Deschemin JC, Vaulont S.

PLoS One. 2013 Apr 23;8(4):e61050. doi: 10.1371/journal.pone.0061050. Print 2013.


Hepatic peroxisome proliferator-activated receptor γ coactivator 1α and hepcidin are coregulated in fasted/refed states in mice.

Deschemin JC, Foretz M, Viollet B, Vaulont S.

Clin Chem. 2012 Oct;58(10):1487-8. Epub 2012 Aug 14. No abstract available.


Deletion of HIF-2α in the enterocytes decreases the severity of tissue iron loading in hepcidin knockout mice.

Mastrogiannaki M, Matak P, Delga S, Deschemin JC, Vaulont S, Peyssonnaux C.

Blood. 2012 Jan 12;119(2):587-90. doi: 10.1182/blood-2011-09-380337. Epub 2011 Nov 29.


Synthesis and biological activity of mouse hepcidin peptide analogs containing three disulfide bridges: manual and microwave-assisted solid-phase peptide synthesis.

Khemtemourian L, Desbenoit N, Mahesh P, Chatterjee S, Deschemin JC, Vaulont S, Tomas A, Sari MA, Artaud I.

Protein Pept Lett. 2012 Feb;19(2):219-27.


Lack of iron-related phenotype in Sp6 intestinal knockout mice.

Matak P, Deschemin JC, Peyssonnaux C, Vaulont S.

Blood Cells Mol Dis. 2011 Jun 15;47(1):46-9. doi: 10.1016/j.bcmd.2011.03.009. Epub 2011 Apr 21.


Is EPO therapy able to correct iron deficiency anaemia caused by matriptase-2 deficiency?

Nicolas G, Deschemin JC, Ramsay AJ, Mayeux P, Grandchamp B, Beaumont C, Velasco G, Vaulont S.

Br J Haematol. 2011 Feb;152(4):498-500. doi: 10.1111/j.1365-2141.2010.08473.x. Epub 2011 Jan 11. No abstract available.


Iron-deficiency anemia from matriptase-2 inactivation is dependent on the presence of functional Bmp6.

Lenoir A, Deschemin JC, Kautz L, Ramsay AJ, Roth MP, Lopez-Otin C, Vaulont S, Nicolas G.

Blood. 2011 Jan 13;117(2):647-50. doi: 10.1182/blood-2010-07-295147. Epub 2010 Oct 12.


Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone.

Chung B, Verdier F, Matak P, Deschemin JC, Mayeux P, Vaulont S.

FASEB J. 2010 Jun;24(6):2093-103. doi: 10.1096/fj.09-152561. Epub 2010 Feb 2.


Hepcidin targets ferroportin for degradation in hepatocytes.

Ramey G, Deschemin JC, Durel B, Canonne-Hergaux F, Nicolas G, Vaulont S.

Haematologica. 2010 Mar;95(3):501-4. doi: 10.3324/haematol.2009.014399. Epub 2009 Sep 22.


Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process.

Gagliardo B, Kubat N, Faye A, Jaouen M, Durel B, Deschemin JC, Canonne-Hergaux F, Sari MA, Vaulont S.

J Hepatol. 2009 Feb;50(2):394-401. doi: 10.1016/j.jhep.2008.09.018. Epub 2008 Dec 4.


Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum.

Gyan E, Frisan E, Beyne-Rauzy O, Deschemin JC, Pierre-Eugene C, Randriamampita C, Dubart-Kupperschmitt A, Garrido C, Dreyfus F, Mayeux P, Lacombe C, Solary E, Fontenay M.

Leukemia. 2008 Oct;22(10):1864-73. doi: 10.1038/leu.2008.172. Epub 2008 Jul 10.


Production of biologically active forms of recombinant hepcidin, the iron-regulatory hormone.

Gagliardo B, Faye A, Jaouen M, Deschemin JC, Canonne-Hergaux F, Vaulont S, Sari MA.

FEBS J. 2008 Aug;275(15):3793-803. doi: 10.1111/j.1742-4658.2008.06525.x. Epub 2008 Jun 28.


Recombinant human IFN-alpha inhibits cerebral malaria and reduces parasite burden in mice.

Vigário AM, Belnoue E, Grüner AC, Mauduit M, Kayibanda M, Deschemin JC, Marussig M, Snounou G, Mazier D, Gresser I, Rénia L.

J Immunol. 2007 May 15;178(10):6416-25.


Pathogenic T cells in cerebral malaria.

Rénia L, Potter SM, Mauduit M, Rosa DS, Kayibanda M, Deschemin JC, Snounou G, Grüner AC.

Int J Parasitol. 2006 May 1;36(5):547-54. Epub 2006 Mar 10. Review.


Species-specific inhibition of cerebral malaria in mice coinfected with Plasmodium spp.

Voza T, Vigário AM, Belnoue E, Grüner AC, Deschemin JC, Kayibanda M, Delmas F, Janse CJ, Franke-Fayard B, Waters AP, Landau I, Snounou G, Rénia L.

Infect Immun. 2005 Aug;73(8):4777-86.


CCR5 deficiency decreases susceptibility to experimental cerebral malaria.

Belnoue E, Kayibanda M, Deschemin JC, Viguier M, Mack M, Kuziel WA, Rénia L.

Blood. 2003 Jun 1;101(11):4253-9. Epub 2003 Jan 30.


On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria.

Belnoue E, Kayibanda M, Vigario AM, Deschemin JC, van Rooijen N, Viguier M, Snounou G, Rénia L.

J Immunol. 2002 Dec 1;169(11):6369-75.


Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.

Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, Dore MX, Guillet JG.

J Invest Dermatol. 2001 Dec;117(6):1464-70.


Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

Dalod M, Dupuis M, Deschemin JC, Goujard C, Deveau C, Meyer L, Ngo N, Rouzioux C, Guillet JG, Delfraissy JF, Sinet M, Venet A.

J Clin Invest. 1999 Nov;104(10):1431-9.


Altered ex vivo balance between CD28+ and CD28- cells within HIV-specific CD8+ T cells of HIV-seropositive patients.

Dalod M, Sinet M, Deschemin JC, Fiorentino S, Venet A, Guillet JG.

Eur J Immunol. 1999 Jan;29(1):38-44.


Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy.

Dalod M, Harzic M, Pellegrin I, Dumon B, Hoen B, Sereni D, Deschemin JC, Levy JP, Venet A, Gomard E.

J Infect Dis. 1998 Jul;178(1):61-9.


Supplemental Content

Loading ...
Support Center